ATE397932T1 - Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien - Google Patents

Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien

Info

Publication number
ATE397932T1
ATE397932T1 AT03723907T AT03723907T ATE397932T1 AT E397932 T1 ATE397932 T1 AT E397932T1 AT 03723907 T AT03723907 T AT 03723907T AT 03723907 T AT03723907 T AT 03723907T AT E397932 T1 ATE397932 T1 AT E397932T1
Authority
AT
Austria
Prior art keywords
ranolazine
arrhythmia
medication
treatment
production
Prior art date
Application number
AT03723907T
Other languages
English (en)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE397932T1 publication Critical patent/ATE397932T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT03723907T 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien ATE397932T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
ATE397932T1 true ATE397932T1 (de) 2008-07-15

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03723907T ATE397932T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien
AT08004276T ATE470445T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08004276T ATE470445T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)

Country Status (20)

Country Link
US (2) US20030220344A1 (de)
EP (3) EP2198866A1 (de)
JP (1) JP4608217B2 (de)
KR (2) KR20100119804A (de)
CN (2) CN100548300C (de)
AT (2) ATE397932T1 (de)
AU (3) AU2003230810B2 (de)
CA (1) CA2481192C (de)
CY (1) CY1110400T1 (de)
DE (2) DE60321550D1 (de)
DK (2) DK1490066T3 (de)
ES (2) ES2345573T3 (de)
HK (1) HK1120390A1 (de)
IL (1) IL197406A0 (de)
MX (1) MXPA04009637A (de)
NO (1) NO330953B1 (de)
NZ (1) NZ535610A (de)
PT (2) PT1930007E (de)
SI (2) SI1930007T1 (de)
WO (1) WO2003086401A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
EP1505977B1 (de) * 2002-05-21 2014-09-10 Gilead Sciences, Inc. Verabreichung eines partiellen fettsäure oxidationshemmers wie ranolazin zur behandlung von diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US7115610B2 (en) * 2003-12-18 2006-10-03 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2005304421A1 (en) * 2004-11-09 2006-05-18 Gilead Palo Alto, Inc. Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
EP1841411A2 (de) * 2005-01-06 2007-10-10 Cv Therapeutics, Inc. Pharmazeutische ranolazinhaltige zusammensetzungen mit verzögerter freisetzung
KR20080028361A (ko) * 2005-05-03 2008-03-31 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 퀴닌-함유 제어-방출형 제제
CA2670651A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117509A1 (de) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Verwendung von ranolazin zur behandlung von herz-kreislauf-erkrankungen
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
US20100056536A1 (en) * 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
US20100113514A1 (en) * 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
EP2847169A4 (de) 2012-05-07 2015-09-30 Cellix Bio Private Ltd Zusammensetzungen und verfahren zur behandlung neurologischer erkrankungen
EP2847158A4 (de) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Zusammensetzungen und verfahren zur behandlung neuromuskulärer erkrankungen und neurodegenerativer erkrankungen
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
EP2852571A4 (de) 2012-05-23 2015-11-25 Cellix Bio Private Ltd Zusammensetzungen und verfahren zur behandlung von mukositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014027262A2 (en) * 2012-08-14 2014-02-20 Mahesh Kandula Compositions and methods for the treatment angina and cardiovascular conditions
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (de) 2012-09-08 2016-02-24 Cellix Bio Private Ltd Zusammensetzungen und verfahren zur behandlung von entzündungen und lipidstörungen
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
EP3027190A1 (de) * 2013-08-01 2016-06-08 Gilead Sciences, Inc. Verbindung und verfahren zur behandlung des long-qt-syndroms
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
KR101617683B1 (ko) 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0407780B1 (de) * 1989-06-23 1996-09-11 Syntex (U.S.A.) Inc. Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
DE69429524T2 (de) * 1993-09-24 2002-08-08 The University Of British Columbia, Vancouver Aminocyclohexylester und ihre anwendung
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP2033633A3 (de) * 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partielle Fettsäurenoxidationsinhibitoren bei der Behandlung von kongestiver Herzinsuffizienz
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
DE60134403D1 (de) * 2000-05-19 2008-07-24 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp-1
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
US20030220344A1 (en) 2003-11-27
WO2003086401A1 (en) 2003-10-23
HK1120390A1 (en) 2009-04-03
SI1490066T1 (sl) 2008-10-31
CA2481192C (en) 2012-07-03
DE60321550D1 (de) 2008-07-24
NZ535610A (en) 2006-05-26
JP2005528393A (ja) 2005-09-22
EP1930007B1 (de) 2010-06-09
CN1646127A (zh) 2005-07-27
US20100004255A1 (en) 2010-01-07
CA2481192A1 (en) 2003-10-23
EP1930007A1 (de) 2008-06-11
ATE470445T1 (de) 2010-06-15
EP1490066B1 (de) 2008-06-11
NO20044783L (no) 2004-11-03
IL197406A0 (en) 2011-07-31
EP1490066A1 (de) 2004-12-29
DK1490066T3 (da) 2008-10-13
DK1930007T3 (da) 2010-08-30
ES2304507T3 (es) 2008-10-16
MXPA04009637A (es) 2005-07-14
AU2011202135A1 (en) 2011-05-26
PT1930007E (pt) 2010-08-17
ES2345573T3 (es) 2010-09-27
PT1490066E (pt) 2008-07-22
CY1110400T1 (el) 2015-04-29
SI1930007T1 (sl) 2010-08-31
DE60332975D1 (de) 2010-07-22
CN100548300C (zh) 2009-10-14
EP2198866A1 (de) 2010-06-23
JP4608217B2 (ja) 2011-01-12
NO330953B1 (no) 2011-08-22
AU2003230810A1 (en) 2003-10-27
AU2009201065B2 (en) 2011-07-21
AU2003230810B2 (en) 2009-02-26
CN101843619A (zh) 2010-09-29
AU2009201065A1 (en) 2009-04-09
KR20100119804A (ko) 2010-11-10
KR20040099395A (ko) 2004-11-26

Similar Documents

Publication Publication Date Title
ATE397932T1 (de) Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien
ATE517658T1 (de) Arrythmie-klassifizierung und therapiewahl
DE60010702D1 (de) Behandlung von titanerz zur herstellung von titandioxidpigmenten
ATE411831T1 (de) Mehrfach-signalmuster zum filtern von fernfeld-r- zacken
EP1803486A3 (de) Verfahren zum Unterscheiden zwischen ventrikulären und supraventrikulären Arrhythmien
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
WO2004062479A3 (en) Non-invasive heart treatment device
CY1106178T1 (el) 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν
WO2006053332A3 (en) Treatment articles capable of conforming to an underlying shape
DE60135755D1 (de) Verbindungen und methoden zur behandlung von hautverletzungen
DE60323994D1 (de) Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan
ATE374619T1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE451091T1 (de) Kosmetisches peeling-verfahren unter verwendung von harnstoff
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
AU4584100A (en) Morphinoid compounds
DE60202446D1 (de) Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
CY1115214T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
ATE497784T1 (de) Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen
DE60336275D1 (de) Verfahren zur Herstellung von 3-(1,3-Dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als Dopamin-beta-hydroxylase Inhibitor
ATE376914T1 (de) Verwendung einer wässrigen lösung mit einem oder mehreren bifluoriden zur verbesserung des trocknungsprozesses von frischholz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1490066

Country of ref document: EP